OXYGENTA PHARMACEUTICAL LIMITED

BSE: OXYGENTAPH524636ISIN INE102E01018

Healthcare
Pharmaceuticals

BSE listing

Share price

₹53.20+0.20 (+0.38%)

as of 18 Sep 2026

52W high: ₹74.00
52W low: ₹43.00
Off 52W high: -28.11%
1M return: -20.86%
3M return: +6.21%
6M return: +9.69%
1Y return: -25.07%
20D avg volume: 11,160
50 DMA: ₹55.09
200 DMA: ₹53.92

Key ratios Standalone

Market cap: ₹196.75 Cr
Current price: ₹53.20
52W high / low: ₹74.00 / ₹43.00
Face value: ₹10.00
P/E: -14.50
P/B: -9.30
EPS (TTM): ₹-3.67
Book value / share: ₹-5.71
ROE: 64.24%
ROCE: -51.80%
Operating margin: 1.54%
Net margin: -5.69%
Debt / equity: -2.57
Net debt: ₹109.15 Cr
Interest cover: -3.64
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: -30.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	37.00	49.61	33.93	14.30	15.13	49.47	—
	0.02	0.17	0.00	-0.06	0.17	0.05	—
	39.53	51.07	40.26	20.68	23.44	53.04	—
	23.40	46.54	31.17	16.97	15.66	44.03	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.95	1.72	1.89	2.03	2.00	2.19	—
	2.46	1.81	1.39	0.95	0.63	2.13	—
	0.62	-0.24	0.86	0.86	0.85	-0.23	—
	4.25	4.58	4.58	4.41	5.01	5.17	—
	-2.51	-1.28	-6.33	-6.44	-8.14	-3.53	—
	0.00	0.00	0.00	0.00	-0.01	-0.27	—
	-2.51	-1.28	-6.33	-6.44	-8.15	-3.80	—
	-0.40	0.42	-1.48	-1.51	-2.04	-1.65	—
	-2.10	-1.70	-4.84	-4.93	-6.11	-2.15	—
	-0.57	-0.45	-1.32	-1.33	-1.65	-0.60	—
Key metrics
	0.57	0.29	-4.08	-4.63	-6.67	-1.90	—
	1.50%	0.60%	-12.00%	-32.40%	-44.10%	-3.80%	—
	-5.70%	-3.40%	-14.30%	-34.50%	-40.40%	-4.30%	—
	—	1.60%	—	66.50%	—	54.80%	—
	144.50%	0.30%	—	—	—	—	—
	65.60%	20.90%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	134.84	112.98	109.30	—
	0.13	0.29	1.31	—
	151.54	135.45	124.69	—
	118.08	110.34	100.23	—
	0.00	0.00	0.00	—
	7.59	7.64	6.90	—
	6.61	4.78	3.61	—
	2.10	2.32	1.78	—
	17.82	18.57	15.92	—
	-16.56	-22.18	-14.08	—
	0.00	0.00	-0.27	—
	-16.56	-22.18	-14.35	—
	-2.97	-4.61	-4.05	—
	-13.57	-17.57	-10.30	—
	-3.67	-4.75	-2.86	—
Key metrics
	-7.85	-15.08	-8.96	—
	-5.82%	-13.30%	-8.20%	—
	-10.06%	-15.60%	-9.40%	—
	—	-51.80%	352.10%	—
	—	3.40%	—	—
	—	-70.60%	—	—
	—	-40.61	-8.79	—
	—	1.58	-0.25	—
	—	-2.57	-2.43	—
	—	109.15	62.23	—
	—	-30.2	-14.0	—
Balance sheet
	—	119.68	82.80	—
	—	51.43	30.94	—
	—	0.42	0.00	—
	—	10.03	5.10	—
	—	29.42	20.51	—
	—	9.83	—	—
	—	47.60	36.83	—
	—	48.77	29.79	—
	—	86.10	85.85	—
	—	109.57	62.23	—
	—	34.28	40.71	—
	—	75.29	21.52	—
	—	-42.69	-25.64	—
Cash flow
	—	-27.75	2.60	—
	—	-14.39	-11.25	—
	—	42.56	8.67	—
	—	12.86	11.39	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 56.53%

Holder	Type	Holding	Previous	Change
Virupaksha Organics Limited	Promoter	56.50%	—	—
SRAVANI REDDY GANTLA	Public	6.78%	—	—
SUBBA REDDY BHIMAVARAPU	Public	4.14%	—	—
SUNIL V. CHAWDA	Public	2.97%	—	—
KUMUDA KATASANI	Public	2.27%	—	—
AAKANKSHA M CHAWDA	Public	1.54%	—	—
MANOJ S. CHAWDA	Public	1.54%	—	—
SNIGDHA VANKINENI	Public	1.47%	—	—
DEVARAPALLY VENKATESWARA REDDY	Public	1.31%	—	—
SATYANARAYANA REDDY BANDI	Public	1.29%	—	—
B SUBBA REDDY	Public	1.26%	—	—
CHANDRA MOULISWAR REDDY GANGAVARAM	Promoter Group	0.03%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Disclosure under Regulation 44(3) of SEBI (LODR), Regulations, 2015.21 Aug 2026 · AGM/EGM / AGM
Outcome of 33rd Annual General Meeting held on 21.08.2026.21 Aug 2026 · AGM/EGM / AGM
Newspaper Advertisement for Notice of AGM scheduled to be held on 21st August, 2026.31 Jul 2026 · Company Update / General
Intimation of Book Closure and Cut-off Date for the AGM30 Jul 2026 · AGM/EGM / AGM
Submission of 33rd Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR), Regulations, 201530 Jul 2026 · Others / Reg. 34 (1) Annual Report
Notice of 33rd Annual General Meeting for the Financial Year 2025-26.30 Jul 2026 · AGM/EGM / AGM
Appointment of Cost Auditor for the Financial Year 2026-27.27 Jul 2026 · Company Update / Change in Management
Un-audited Financial Results for the Quarter ended 30.06.2026.27 Jul 2026 · Result / Financial Results
Un-audited Financial results for the Quarter ended 30.06.2026.27 Jul 2026 · Board Meeting / Outcome of Board Meeting
The Board Meeting to be held on 25/07/2026 has been revised to 27/07/2026 Postponement of the Board Meeting to be held on Saturday, 25th July, 2026 and rescheduling of the board meeting ....24 Jul 2026 · Company Update / Board Meeting Rescheduled
Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2026 ,inter alia, to consider and approve 1. Unaudited Financial ....22 Jul 2026 · Board Meeting / Board Meeting
Compliance as per Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th June, 2026.14 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of trading window for the period ending 30.06.2026.24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Annual Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Regulation 24A of SEBI (LODR) Regulations, 2018.26 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Change in Management by way of appointment of Additional Directors and Internal Auditor.23 May 2026 · Company Update / Change in Management
Audited Financial Results for the Quarter and Year ended 31.03.2026.23 May 2026 · Result / Financial Results
Outcome of the Board meeting held on 23rd May, 2026.23 May 2026 · Board Meeting / Outcome of Board Meeting
Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve 1. Audited Financial ....19 May 2026 · Board Meeting / Board Meeting
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''> <tr> <td>Sr. No.</td> <td>Particulars</td> ....27 Apr 2026 · Others / Format of the Annual Disclosure to be made by an entity identified as a LC : Annexure B2
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....27 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Compliance as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 31st March, 202615 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the period ending on 31.03.2026.25 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Disclosure under Regulation 30 of SEBI (Listing Obligations and Discloure Requirements) Regulations, 2015.20 Feb 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd14 Feb 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd13 Feb 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Un-audited Results for the Quarter and nine months ended 31.12.2025.4 Feb 2026 · Result / Financial Results
With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Wednesday, 04th February, 2026, ....4 Feb 2026 · Board Meeting / Outcome of Board Meeting
Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 ,inter alia, to consider and approve 1. Un-audited Financial ....30 Jan 2026 · Board Meeting / Board Meeting
Compliance as per Regulation 74(5) of the SEBI (Depositories and Participants), Regulations, 2018 for the quarter ended 31st December, 2025.12 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window under SEBI (Prohibition of Insier Trading) Regulations, 2015 for the period ending on December 31, 2025.29 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd17 Dec 2025 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd17 Dec 2025 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Reclassification of promoters to public11 Dec 2025 · Company Update / General
Minutes of the resolution passed by way Postal Ballot11 Dec 2025 · AGM/EGM / Postal Ballot
Scrutinizer''s report of postal ballot11 Dec 2025 · AGM/EGM / Postal Ballot
Outcome of the Postal Ballot11 Dec 2025 · AGM/EGM / Postal Ballot
Submission of Newspaper Publications12 Nov 2025 · Company Update / Newspaper Publication
Calendar of Events of Postal Ballot11 Nov 2025 · Company Update / General
Notice of Postal Ballot - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclsoure Requirements), Regulations, 2015.11 Nov 2025 · AGM/EGM / Postal Ballot
Appointment of Mr. Prasad Reddy Battinapatla as Chief Financial Officer of the Company7 Nov 2025 · Company Update / Change in Management

Board meetings

27 Jul 2026 Board Meeting - Financial Results
25 Jul 2026 Board Meeting - Financial Results